CRYO-CELL INTERNATIONAL, INC. (OTCMKTS:CCEL) Files An 8-K Entry into a Material Definitive Agreement

CRYO-CELL INTERNATIONAL, INC. (OTCMKTS:CCEL) Files An 8-K Entry into a Material Definitive Agreement
Item 1.01. Entry into a Material Definitive Agreement.

Effective June 9, 2020, Cryo-Cell International, Inc. (“Cryo-Cell”) entered into a Patent Option Agreement (the “Option”) with Duke University (“Duke”). The Option grants Cryo-Cell the exclusive option to obtain an exclusive license to certain of Duke’s patent rights to make, have made, use, import, offer for sale, sell and otherwise commercially exploit (with the right to sublicense) certain licensed products and to practice certain licensed processes, and the exclusive right to use certain regulatory data and technical information in connection with such licensed patent rights, in the treatment, prevention, cure, reduction, mitigation or other management of diseases in humans, except, with regard to certain patent rights, in certain excluded fields of use and in certain territories, as well as a limited license to make, have made or use certain products, processes, data and information for the purpose of evaluating the market potential for such products and processes in the designated field of use, subject to Duke’s reserved rights to practice the licensed rights for all research, public service, internal (including clinical) and/or educational purposes. to the Option, the terms of any such license are to include the terms (including the fees and royalties) set forth in summary term sheet attached as Appendix A to the Option.

This exclusive Option is for a period of six (6) months from the effective date of the Option. As consideration for the Option, Cryo-Cell will pay Duke a non-refundable, option fee of Three Hundred Fifty Dollars ($350,000). Such option fee, plus any extension fee, will be fully credited against the license fee under the future license agreement. The Option is subject to extension by Cryo-Cell for an additional six (6) months by payment of One Hundred Fifty Thousand Dollars ($150,000) on or before the expiration of the initial six (6) month option period.

The foregoing summary of the Option is not complete and is qualified in its entirety by reference to the Option, a copy of which is attached hereto as Exhibits 10.1 and incorporated by reference.

Item 9.01. Financial Statements and Exhibits.

10.1    Patent Option Agreement, dated June 9, 2020, between Duke University and Cryo-Cell International, Inc.
99.1    Press Release dated June 11, 2020

Story continues below


CRYO CELL INTERNATIONAL INC Exhibit
EX-10.1 2 d943128dex101.htm EX-10.1 EX-10.1 Exhibit 10.1 PATENT OPTION AGREEMENT Duke University File(s) #4719,…
To view the full exhibit click here

About CRYO-CELL INTERNATIONAL, INC. (OTCMKTS:CCEL)

Cryo-Cell International, Inc. is engaged in cellular processing and cryogenic storage. The Company’s segments include cellular processing and cryogenic storage, with a focus on the collection and preservation of umbilical cord blood and tissue stem cells for family use and the manufacture of Prepacyte CB units, the processing technology used to process umbilical cord blood stem cells. The Company, in combination with its global affiliates, stores over 300,000 cord blood and cord tissue specimens around the world. The specimens are stored in commercially available cryogenic storage units at the facility in Oldsmar, Florida. The Company offers the cord tissue service in combination with the umbilical cord blood service. The Company markets its cord blood stem cell preservation services directly to expectant parents and by distributing information through obstetricians, pediatricians, childbirth educators, certified nurse-midwives and other related healthcare professionals.

An ad to help with our costs